Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study
• This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Market Segmentation
• By Product Type
o Viral Vector
 Retroviral Vectors
 Adenoviral Vectors
 Lentiviral Vectors
 Adeno-associated Viral Vectors
 Others
o Plasma DNA
o Non-viral DNA Vectors
• By Therapeutic Application
o Cancer
o Inherited Disorders
o Vitrectomy Surgery Devices
o Infectious Diseases
o Others
• By End Product
o DNA Vaccines
o Gene Therapy
o Immunotherapy
o Others
• By Region
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Europe
 Germany
 U.K.
 France
 Italy
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East
 GCC
 Israel
 Rest of Middle East
o Africa
 South Africa
 Central Africa
 North Africa
• Key Players
o Lonza Group AG
o FinVector Vision Therapies
o Cobra Biologics and Pharmaceutical Services
o Sigma-Aldrich Co. LLC
o VGXI, Inc.
o VIROVEK
o SIRION Biotech GmbH
o FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
o Sanofi
o Cell and Gene Therapy Catapult
o Brammer Bio
o MassBiologics

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 Market Snippet, By Product Type
 Market Snippet, By Therapeutic Application
 Market Snippet, By End Product
 Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
 Drivers
 Restraints
 Market Opportunities
o Impact Analysis of DROs
o Comparative Analysis of Different Types of Viral Systems
o Collaborations, Partnerships, And Agreements
o Pipeline Analysis
o New Product Launches
o Investment Opportunities
o Regulatory Scenario
o Strategies For Product Development and Application Pathways
o Brand Analysis
o Cell & Gene Therapy Manufacturing Capacities Globally
o Porter’s Analysis
4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2021 – 2033
 Segment Trends
o Viral Vector
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retroviral Vectors
o Adenoviral Vectors
o Lentiviral Vectors
o Adeno-associated Viral Vectors
o Others
o Plasma DNA
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Non-Viral DNA Vectors
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2021 – 2033
 Segment Trends
o Cancer
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Inherited Disorders
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Infectious Diseases
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2021 – 2033
 Segment Trends
o DNA Vaccines
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Gene Therapy
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Immunotherapy
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, By Region, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, For Regions, 2017–2027
o North America
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
 Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country/Region, 2021 – 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
 Lonza Group AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 FinVector Vision Therapies
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Cobra Biologics and Pharmaceutical Services
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Sigma-Aldrich Co. LLC
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 VGXI, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 VIROVEK
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 SIRION Biotech GmbH
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Sanofi
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Cell and Gene Therapy Catapult
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Brammer Bio
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 MassBiologics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
Browse 34 market data tables and 33 figures on Viral Vector and Plasmid DNA Manufacturing Market” - Global forecast to 2033.